In this closing segment, the panel reflects on ongoing unmet needs in the first line management of EGFR mutated metastatic non-small cell lung cancer. The discussion highlights challenges in optimizing sequencing strategies, improving access to second line therapies, and ensuring that a greater proportion of patients are able to receive subsequent treatment after progression. Panelists note that while combination regimens have improved outcomes, a significant number of patients do not reach later lines of therapy, underscoring the importance of strategic upfront decision making.
Emerging research directions include refining biomarker driven selection, improving CNS specific control, and developing novel therapeutic approaches that may further extend survival while maintaining tolerability. The segment concludes with final remarks from Dr. Devarakonda, who thanks the panel and emphasizes the importance of integrating evolving clinical data with patient centered care. The program closes by reinforcing the goal of advancing informed, individualized treatment in EGFR mutated metastatic non-small cell lung cancer.
